PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D growth above 1.5x TRVN's 44.02%. Michael Burry would check for spending discipline.
34.89%
G&A growth above 1.5x TRVN's 2.46%. Michael Burry would check for operational inefficiency.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
59.22%
Operating expenses growth above 1.5x TRVN's 35.08%. Michael Burry would check for inefficiency.
59.22%
Total costs growth above 1.5x TRVN's 35.08%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
77.92%
D&A growth above 1.5x TRVN's 17.79%. Michael Burry would check for excessive investment.
-37.27%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-272.88%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-313.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
10.47%
Share count reduction below 50% of TRVN's 0.15%. Michael Burry would check for concerns.
-20.54%
Diluted share reduction while TRVN shows 0.15% change. Joel Greenblatt would examine strategy.